Nasal administration

Abstract

A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit which is operable to deliver the powdered substance through the nosepiece.

1 - 92 . (canceled) 
     
     
         93 . A device for delivering a powdered sumatriptan substance to a nasal cavity of a subject having a nasal cavity, comprising:
 a nosepiece configured for fitting to a nostril of the subject; and   a substance containing unit connected to the nosepiece, the substance containing unit comprising the powdered sumatriptan substance to be delivered to the nasal cavity of the subject, the powdered sumatriptan substance having an untapped bulk density of between about 0.3 g/ml and 0.5 g/ml, wherein at least 50% of the particles of the powdered sumatriptan substance are larger than about 30 μm;   wherein the device is configured such that, when the nosepiece is fitted to the nostril of the subject, oral exhalation by the subject through the substance containing unit and the nosepiece acts to close the oropharyngeal velum of the subject and produce an exhalation flow passing into one nasal passage of the subject and out of the other nasal passage of the subject, thereby achieving a bi-directional exhalation flow for delivering the powdered sumatriptan substance to a portion of the nasal cavity of the subject.   
     
     
         94 . The device of  claim 93 , wherein the powdered sumatriptan substance comprises a sumatriptan base or sumatriptan succinate. 
     
     
         95 . The device of  claim 93 , wherein the powdered sumatriptan substance contains only sumatriptan succinate and no introduced excipients or adjuvants. 
     
     
         96 . The device of  claim 93 , wherein the powdered sumatriptan substance to be delivered to the nasal cavity of the subject is disposed in a substance container. 
     
     
         97 . The device of  claim 96 , wherein the substance container is a capsule. 
     
     
         98 . The device of  claim 96 , wherein the substance container contains a 10 mg dose. 
     
     
         99 . The device of  claim 93 , wherein the powdered sumatriptan substance to be delivered to the nasal cavity of the subject is disposed in a capsule. 
     
     
         100 . The device of  claim 93 , wherein the powdered sumatriptan substance has a particle size distribution of 10% less than about 10 μm, 50% less than about 30 μm and 90% less than about 90 μm. 
     
     
         101 . The device of  claim 93 , further including a trap disposed between the substance containing unit and the nosepiece. 
     
     
         102 . A device for delivering a powdered sumatriptan substance to a nasal cavity of a subject having a nasal cavity, comprising:
 a mouthpiece configured for fitting to an oral cavity of the subject;   a nosepiece configured for fitting to a nostril of the subject; and   a substance containing unit connected to the nosepiece, the substance containing unit comprising the powdered sumatriptan substance to be delivered to the nasal cavity of the subject, the powdered sumatriptan substance having an untapped bulk density of between about 0.3 g/ml and 0.5 g/ml, wherein at least 50% of the particles of the powdered sumatriptan substance are larger than about 30 μm;   wherein the device is configured such that, when the nosepiece is fitted to the nostril of the subject and the mouthpiece is fitted to the oral cavity of the subject, oral exhalation by the subject through the mouthpiece, through the substance containing unit, and through the nosepiece acts to close the oropharyngeal velum of the subject and produce an exhalation flow passing into one nasal passage of the subject and out of the other nasal passage of the subject, thereby achieving a bi-directional exhalation flow for delivering the powdered sumatriptan substance to a portion of the nasal cavity of the subject.   
     
     
         103 . The device of  claim 102 , wherein the powdered sumatriptan substance comprises a sumatriptan base or sumatriptan succinate. 
     
     
         104 . The device of  claim 102 , wherein the powdered sumatriptan substance contains only sumatriptan succinate and no introduced excipients or adjuvants. 
     
     
         105 . The device of  claim 102 , wherein the powdered sumatriptan substance to be delivered to the nasal cavity of the subject is disposed in a substance container. 
     
     
         106 . The device of  claim 105 , wherein the substance container is a capsule. 
     
     
         107 . The device of  claim 105 , wherein the substance container contains a 10 mg dose. 
     
     
         108 . The device of  claim 102 , wherein the powdered sumatriptan substance to be delivered to the nasal cavity of the subject is disposed in a capsule. 
     
     
         109 . The device of  claim 102 , wherein the powdered sumatriptan substance has a particle size distribution of 10% less than about 10 μm, 50% less than about 30 μm and 90% less than about 90 μm. 
     
     
         110 . The device of  claim 102 , further including a trap disposed between the substance containing unit and the nosepiece. 
     
     
         111 . The device of  claim 102 , further including a labyrinthine structure disposed between the mouthpiece and the substance containing unit.